Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of
pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage
II/IIIA suitable for curative intent surgery.